NeurAxis, Inc. ( (NRXS) ) has released its Q2 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies for chronic conditions in both children and adults, with a focus on advancing its proprietary IB-Stim™ therapy.
In its second quarter of 2025, NeurAxis reported a significant 46% increase in revenues, reaching $894,000 compared to the same period last year. The company also noted a decrease in operating expenses by 10% and an improvement in operating loss by 22% year-over-year.
Key financial metrics highlighted include a substantial rise in unit sales by 58%, driven by increased insurance reimbursements and a financial assistance program. Despite a decline in gross margin to 83.6% due to higher discounting, the company secured $5 million through an equity-only financing round. NeurAxis also achieved several operational milestones, including FDA clearances and expanded insurance coverage.
Looking ahead, NeurAxis management remains optimistic about the company’s growth trajectory, emphasizing the potential for substantial revenue growth and improved margins as they expand insurance coverage and commercialize IB-Stim on a larger scale. The company aims to achieve breakeven by 2026, supported by strategic positioning and strong revenue momentum.